Lupin Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Lupin is de winst gegroeid met een gemiddeld jaarlijks percentage van 28.8%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 13.4%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 3.9% per jaar. Het rendement op eigen vermogen van Lupin is 15.9%, en het heeft een nettomarge van 10.9%.

Belangrijke informatie

28.8%

Groei van de winst

28.7%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	17.5%
Inkomstengroei	3.9%
Rendement op eigen vermogen	15.9%
Nettomarge	10.9%
Volgende winstupdate	07 Nov 2024

Recente prestatie-updates uit het verleden

Recent updates

With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

Sep 17

Lupin Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 09

Unpleasant Surprises Could Be In Store For Lupin Limited's (NSE:LUPIN) Shares

Aug 01

Lupin Limited (NSE:LUPIN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Jul 13

Lupin's (NSE:LUPIN) Dividend Will Be Increased To ₹8.00

Jul 12

These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely

Jun 15

Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results

May 09

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 10

Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk

Jan 19

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Nov 10

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Jun 23

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Mar 24

Lupin's (NSE:LUPIN) Dividend Is Being Reduced To ₹4.00

Jul 08

Opbrengsten en kosten

Hoe Lupin geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NSEI:LUPIN Opbrengsten, kosten en inkomsten (INR Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	207,971	22,635	37,196	0
31 Mar 24	200,108	19,145	35,930	0
31 Dec 23	194,801	17,910	34,647	0
30 Sep 23	186,049	13,314	33,394	0
30 Jun 23	177,119	9,714	32,504	0
31 Mar 23	166,417	4,301	31,845	0
31 Dec 22	160,946	-3,239	31,090	0
30 Sep 22	159,333	682	30,889	0
30 Jun 22	158,791	-21,596	30,758	0
31 Mar 22	164,055	-15,280	30,810	0
31 Dec 21	163,052	-5,497	30,151	0
30 Sep 21	161,616	-6,570	29,780	0
30 Jun 21	159,053	16,521	29,047	0
31 Mar 21	151,630	12,165	29,146	0
31 Dec 20	152,260	11,458	30,368	0
30 Sep 20	149,777	-1,609	30,707	0
30 Jun 20	150,249	-5,572	31,456	0
31 Mar 20	153,748	-3,995	30,744	0
31 Dec 19	174,693	-4,428	35,429	0
30 Sep 19	176,892	3,138	34,959	0
30 Jun 19	172,806	7,068	34,394	0
31 Mar 19	146,646	5,121	29,658	0
31 Dec 18	163,114	-4,665	32,875	0
30 Sep 18	157,822	-931	31,721	0
30 Jun 18	157,829	960	31,033	0
31 Mar 18	157,765	2,513	30,718	0
31 Dec 17	159,233	14,150	30,361	0
30 Sep 17	164,306	18,264	30,717	0
30 Jun 17	167,693	20,336	30,567	0
31 Mar 17	173,674	25,575	30,419	0
31 Dec 16	173,910	29,351	28,249	0
30 Sep 16	164,558	28,265	26,372	0
30 Jun 16	154,918	25,841	24,576	0
31 Mar 16	141,316	22,607	22,931	0
31 Dec 15	131,055	20,106	36,592	1,682
30 Sep 15	127,273	20,823	35,467	1,682
30 Jun 15	125,794	23,035	34,614	1,682
31 Mar 15	127,700	24,032	18,570	0
31 Dec 14	128,124	24,092	32,709	1,311
30 Sep 14	126,567	22,839	32,337	1,311
30 Jun 14	121,512	20,601	31,630	1,311
31 Mar 14	112,866	18,364	30,808	1,311
31 Dec 13	107,519	16,915	28,011	890

Kwaliteitswinsten: LUPIN heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (10.9%) LUPIN } zijn hoger dan vorig jaar (5.5%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van LUPIN is de afgelopen 5 jaar aanzienlijk gegroeid met 28.8% per jaar.

Versnelling van de groei: De winstgroei van LUPIN over het afgelopen jaar ( 133% ) overtreft het 5-jarig gemiddelde ( 28.8% per jaar).

Winst versus industrie: De winstgroei LUPIN over het afgelopen jaar ( 133% ) overtrof de Pharmaceuticals -sector 19.1%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 15.9% ) van LUPIN wordt als laag beschouwd.

Lupin Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Lupin Limited to Report Q2, 2025 Results on Nov 07, 2024

Lupin Limited to Report Q1, 2025 Results on Aug 06, 2024

Full year 2024 earnings: EPS misses analyst expectations

Full year 2024 earnings: EPS misses analyst expectations

Lupin Limited to Report Q4, 2024 Results on May 06, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Lupin Limited to Report Q2, 2025 Results on Nov 07, 2024

Lupin Limited Announces its Wholly Owned Subsidiary Lupin Management, Inc., USA Appoints Claus Jepsen as President, Global Specialty

Lupin Launches First Generic of Pred Forte® in the United States

With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

Price target increased by 12% to ₹1,835

Lupin Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Lupin Limited Announces Change of Company Secretary and Compliance Officer

Lupin Limited Approves Dividend for Year Ended March 31, 2024

Unpleasant Surprises Could Be In Store For Lupin Limited's (NSE:LUPIN) Shares

Lupin Limited to Report Q1, 2025 Results on Aug 06, 2024

Lupin Limited (NSE:LUPIN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Lupin's (NSE:LUPIN) Dividend Will Be Increased To ₹8.00

Full year 2024 earnings: EPS misses analyst expectations

Dividend increased to ₹8.00

Lupin Limited, Annual General Meeting, Aug 02, 2024

These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely

Lupin Limited Announces Board Appointments

Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results

New minor risk - Dividend sustainability

With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

Full year 2024 earnings: EPS misses analyst expectations

Lupin Limited to Report Q4, 2024 Results on May 06, 2024

Investor Optimism Abounds Lupin Limited (NSE:LUPIN) But Growth Is Lacking

Lupin Limited Announces Change in Management

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.075% in the United States

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Price target increased by 12% to ₹1,355

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lupin Limited Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.075%

Insufficient new directors

Lupin Limited to Report Q3, 2024 Results on Feb 07, 2024

Lupin Receives Approval from U.S. FDA for Febuxostat Tablets

Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk

Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.07% in the United States

Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.2%

Lupin Limited Receives Tentative Approval from U.S. FDA for Canagliflozin Tablets

Lupin Limited Launches First Fixed-Dose Triple Combination Drug, Vilfuro-G® for COPD Management in India

Lupin Limited Receives Tentative Approval from U.S. FDA for Dapagliflozin Tablets

Price target increased by 8.2% to ₹1,067

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lupin Limited to Report Q2, 2024 Results on Nov 08, 2023

Lupin Limited Receives Tentative Approval from U.S. FDA for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution

Lupin Limited (BSE:500257) completed the acquisition of Ondero and Ondero - Met from Boehringer Ingelheim International GmbH.

Price target increased by 15% to ₹878

Lupin Limited Approves Dividend for the Year Ended March 31, 2023

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Lupin Limited Receives Tentative Approval from U.S. Fda for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Lupin Limited Receives EIR from U.S. FDA for its Pithampur Unit-2 Manufacturing Facility

Upcoming dividend of ₹4.00 per share at 0.4% yield

Lupin Limited, Annual General Meeting, Aug 03, 2023

Lupin Limited Receives Approval from U.S. Fda for Cyanocobalamin Nasal Spray

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Lupin Limited Launches Thiamine Hydrochloride Injection USP in the United States

Lupin Launches Darunavir Tablets in the United States

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Third quarter 2023 earnings: Revenues in line with analyst expectations

Lupin Receives Approval from US FDA for Glycopyrrolate Injection, USP

Lupin Limited Receives Tentative Approval from U.S. FDA for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets

Lupin Limited to Report Q3, 2023 Results on Feb 09, 2023

Lupin Limited Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients

Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets

Lupin and Exeltis Announce Reimbursement Approval of NaMuscla in Spain for the Symptomatic Treatment of Myotonia in Adults with Non-Dystrophic Myotonic Disorders

Lupin Receives Approval from U.S. FDA for Fesoterodine Fumarate Extended-Release Tablets

Lupin Limited Launches Novel Fixed-Dose Triple Drug Combination Difizma® Dpi to Treat Inadequately Controlled Asthma